Therapeutic equivalency of low-molecular-weight heparins

Annals of Pharmacotherapy

Volumn 36, Issue 6, 2002, Pages 1042-1057

  McCart, Gary M ^a   Kayser, Steven R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ardeparin; Dalteparin; Deep vein thrombosis; Enoxaparin; General surgery; Low molecular weight heparin; Tinzaparin; Total hip replacement; Total knee replacement; Unstable angina

Indexed keywords

ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN; WARFARIN; ANTICOAGULANT AGENT;

ARTICLE; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; GENERAL SURGERY; HEART INFARCTION; HEMATOMA; HUMAN; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; THROMBOSIS; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; UNSTABLE ANGINA PECTORIS; ANIMAL; CONTROLLED CLINICAL TRIAL; HIP ARTHROPLASTY; KNEE ARTHROPLASTY; META ANALYSIS; PHARMACOKINETICS; REVIEW; VEIN THROMBOSIS;

ANGINA, UNSTABLE; ANIMALS; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CONTROLLED CLINICAL TRIALS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; THERAPEUTIC EQUIVALENCY; VENOUS THROMBOSIS;

EID: 0036014077     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10264     Document Type: Article

References (66)

1. Heparin and low-molecular weight heparin
2. Low-molecular-weight heparins
3. Grades of recommendation for antithrombotic agents
4. Are the available low molecular weight heparin preparations the same?
5. Low molecular weight heparin: Differences and similarities in approved preparations in the United States
6. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition
7. Low molecular weight heparin therapy: Is monitoring needed?
8. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparin: Low molecular weight heparin to prevent deep vein thrombosis after hip replacement
9. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-Ia activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery
10. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin
11. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy
12. Dosing and monitoring of low-molecular weight heparin in special populations
13. Effects of unfractionated heparin, low molecular-weight-heparin and heparinoid on thromboelastographic assay of blood coagulation
14. Prevention of venous thromboembolism
15. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin
16. Rates of venous thrombosis after general surgery: Combined results of randomized clinical trials
17. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis
18. Low molecular weight heparin in the prevention of deep vein thrombosis in general surgery
19. Prevention of venous thromboembolism in general surgery
20. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?
21. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery
22. Efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment
23. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery
24. Prevention of venous thromboembolism after knee arthroplasty
25. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: A double-blind, dose-ranging study
26. Low-molecularweight heparin and partial thromboplastin time adjusted unfractionated heparin in thromboprophylaxis after total knee and total hip arthroplasty
27. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty
28. Prevention of deep vein thrombosis after hip replacement
29. Prevention of deep-vein thrombosis after total hip arthroplasty
30. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs. warfarin in hip arthroplasty patients
31. Management of deep vein thrombosis and pulmonary embolism
32. The natural history and epidemiology of venous thrombosis
33. Deep-vein thrombosis
34. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism
35. Antithrombotic therapy for venous thromboembolic disease
36. Subcutaneous low-molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis
37. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy
38. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy
39. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
40. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease
41. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis
42. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis
43. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
44. Low-molecular-weight heparin vs. heparin in the treatment of patients with pulmonary embolism
45. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina
46. Aspirin, heparin or both to treat unstable angina
47. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
48. Comparison of the effect of heparin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina
49. Antithrombotic agents in coronary artery disease
50. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
51. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE study: Eficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events
52. Meeting highlights: 47th Annual Scientific Sessions of the American College of Cardiology
53. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
54. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis
55. Low-molecular-weight heparin during instability in coronary artery disease
56. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease FRISC II) investigators
57. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC)
58. Unfractionated heparin dosing in the FRIC study
59. Low molecular-weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared to unfractionated heparin?
60. Differentiation of the low-molecular-weight heparins
61. Low-molecular weight heparins are essentially the same for treatment and prevention of venous thomboembolism
62. Comparison of two low molecular weight heparins for the prevention of post operative venous thromboembolism after elective hip surgery